Nektar Therapeutics (NASDAQ: NKTR) is -5.59% lower on its value in year-to-date trading and has touched a low of $0.65 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NKTR stock was last observed hovering at around $0.86 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $0.88, the stock is 3.49% and -1.51% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.84 million and changing 1.95% at the moment leaves the stock -24.57% off its SMA200. NKTR registered -0.69% loss for a year compared to 6-month loss of -29.19%.
The stock witnessed a 15.53% gain in the last 1 month and extending the period to 3 months gives it a -17.94%, and is 4.52% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.08% over the week and 11.38% over the month.
Nektar Therapeutics (NKTR) has around 137 employees, a market worth around $161.95M and $93.14M in sales. Profit margin for the company is -180.70%. Distance from 52-week low is 35.08% and -54.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.09%).
with sales reaching $36.66M over the same period.The EPS is expected to grow by 50.57% this year, but quarterly earnings will post 17.53% year-over-year. Quarterly sales are estimated to grow 53.48% in year-over-year returns.
Nektar Therapeutics (NKTR) Top Institutional Holders
The shares outstanding are 184.46M, and float is at 177.79M with Short Float at 4.21%.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 17.88 million shares valued at $22.17 million. The investor’s holdings represent 8.5599% of the NKTR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 15.16 million shares valued at $18.79 million to account for 7.7823 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 12.97 million shares representing 6.6587% and valued at over $16.08 million, while SAMLYN CAPITAL, LLC holds 4.529 of the shares totaling 9.46 million with a market value of $11.73 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Zalevsky Jonathan, the company’s Chief R&D Officer. SEC filings show that Zalevsky Jonathan sold 10,300 shares of the company’s common stock on Feb 19 ’25 at a price of $1.01 per share for a total of $10403.0. Following the sale, the insider now owns 0.32 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Feb 19 ’25 that Wilson Mark Andrew (Chief Legal Officer) sold a total of 11,040 shares of the company’s common stock. The trade occurred on Feb 19 ’25 and was made at $1.01 per share for $11150.0. Following the transaction, the insider now directly holds 0.32 million shares of the NKTR stock.
Still, SEC filings show that on Feb 19 ’25, ROBIN HOWARD W (President & CEO) disposed off 23,774 shares at an average price of $1.01 for $24012.0. The insider now directly holds 1,086,901 shares of Nektar Therapeutics (NKTR).
